

Appl. No. 10/053,302  
Amendment dated May 31, 2005  
Reply to Final Office Action February 28, 2005

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Previously presented) An anti-IFNAR2 antibody selected from the group consisting of antibody 1F3 produced by a hybridoma with ATCC Accession No. HB 12426 or progeny thereof, antibody 3B7 produced by a hybridoma with ATCC Accession No. HB 12427 or progeny thereof, and antibody 1D3 produced by the hybridoma with ATCC Accession No. HB 12428 or progeny thereof.
2. (Original) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with the antibody of claim 1.
3. (Currently amended) A polypeptide comprising a portion of the antibody of claim 1 or 2, wherein said portion comprises an antigen binding fragment ~~or a variable region~~ of said antibody.
4. (Canceled)
5. (Original) The antibody of claim 2, wherein said antibody does not substantially block binding of a Type I interferon to IFNAR2.
6. (Original) The antibody of claim 5, wherein said Type I interferon is IFN $\alpha$ -2/1.
7. (Original) The antibody of claim 5, wherein said antibody blocks anti-viral activity of a first Type I interferon and does not block anti-viral activity of a second Type I interferon.

Appl. No. 10/053,302  
Amendment dated May 31, 2005  
Reply to Final Office Action February 28, 2005

8 (Previously presented) The antibody of claim 5, wherein said antibody competes for binding to IFNAR2 with antibody 1D3 produced by a hybridoma with ATCC Accession No. HB 12428 or progeny thereof.

9. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a monoclonal antibody.

10. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a humanized antibody.

11. (Previously presented) The antibody of claim 2 or 3, wherein said antibody is a human antibody.

12-13. (Canceled)

14. (Previously presented) A composition comprising the antibody of claims 1-3 or 9-11 and an excipient.

15. (Previously presented) An anti-IFNAR2 antibody IF3 produced by a hybridoma with ATCC Accession No. HB 12426 or progeny thereof.

16. (Previously presented) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody IF3 produced by hybridoma with ATCC Accession No. HB 12426 or progeny thereof.

17. (Previously presented) An anti-IFNAR2 antibody 3B7 produced by a hybridoma with Accession No. HB 12427 or progeny thereof.

Appl. No. 10/053,302  
Amendment dated May 31, 2005  
Reply to Final Office Action February 28, 2005

18. (Previously presented) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody 3B7 produced by hybridoma with ATCC Accession No. HB 12427 or progeny thereof.

19. (Currently amended) An anti-IFNAR2 antibody ~~ID3~~ 1D3 produced by a hybridoma with ATCC Accession No. HB 12428 or progeny thereof.

20. (Currently amended) An anti-IFNAR2 antibody that competes for binding to IFNAR2 with antibody ~~ID3~~ 1D3 produced by hybridoma with ATCC Accession No. HB 12428 or progeny thereof.

21. (New) The antibody of claim 7, wherein the antibody blocks the activity of IFN- $\alpha$ 8, IFN- $\alpha$ 5, IFN- $\alpha$ 2, and IFN- $\alpha$ 1.

22. (New) The antibody of claim 21, wherein the second Type I interferon is IFN- $\beta$ .

23. (New) The antibody of claim 1, wherein the antibody blocks IGSF complex formation.